

Fernando Caravaggio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6725439/publications.pdf>

Version: 2024-02-01

95
papers

2,133
citations

257450

24
h-index

265206

42
g-index

96
all docs

96
docs citations

96
times ranked

3292
citing authors

#	ARTICLE	IF	CITATIONS
1	A measure of subjective substance use disorder awareness â€” Substance Use Awareness and Insight Scale (SAS). <i>Drug and Alcohol Dependence</i> , 2022, 231, 109129.	3.2	3
2	Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 1205-1213.	6.1	13
3	MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3341-3350.	2.4	2
4	Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia. <i>Schizophrenia Research</i> , 2022, 241, 113-115.	2.0	1
5	The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans. <i>European Neuropsychopharmacology</i> , 2022, 57, 39-49.	0.7	2
6	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. <i>Molecular Psychiatry</i> , 2022, 27, 2950-2967.	7.9	44
7	P560. Impaired Obesity Awareness May Be Related to Interhemispheric Imbalance in the Posterior Parietal Areas. <i>Biological Psychiatry</i> , 2022, 91, S315-S316.	1.3	0
8	P550. GABA Alteration in Patients With Treatment-Resistant Schizophrenia: A 1H-MRS Study. <i>Biological Psychiatry</i> , 2022, 91, S311.	1.3	0
9	Structural Brain Differences Between Cognitively Impaired Patients With and Without Apathy. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 319-332.	1.2	12
10	Lower striatal dopamine D2/3receptor availability in obsessive-compulsive disorder: A meta-analysis of [¹¹ C]-raclopride and [¹²³ I]-IBZM studies. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2021, 28, 100618.	1.5	1
11	Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab006.	1.7	14
12	Measuring amphetamineâ€”induced dopamine release in humans: A comparative metaâ€”analysis of [¹¹ C]-raclopride and [¹¹ C]-PHNO studies. <i>Synapse</i> , 2021, 75, e22195.	1.2	9
13	Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2021, 136, 468-473.	3.1	4
14	Increased Regional Cerebral Blood Flow in the Parietal Regions in Patients With Schizophrenia With Impaired Insight. <i>Biological Psychiatry</i> , 2021, 89, S263-S264.	1.3	0
15	Neuromelanin Accumulation in Patients With Schizophrenia: A Systematic Review and Meta-Analysis. <i>Biological Psychiatry</i> , 2021, 89, S253.	1.3	1
16	A Measure to Assess Illness Awareness in Problem Gambling: Gambling Awareness and Insight Scale (GAS). <i>Journal of Gambling Studies</i> , 2021, , 1.	1.6	4
17	A measure of illness awareness in alcohol use disorderâ€”Alcohol Use Awareness and Insight Scale (AAS). <i>Drug and Alcohol Dependence</i> , 2021, 226, 108813.	3.2	4
18	Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. <i>NeuroImage: Clinical</i> , 2021, 32, 102852.	2.7	9

#	ARTICLE	IF	CITATIONS
19	Individual determinants of COVID-19 vaccine hesitancy. PLoS ONE, 2021, 16, e0258462.	2.5	109
20	Anti-vaccination attitudes are associated with less analytical and more intuitive reasoning. Psychology, Health and Medicine, 2021, , 1-13.	2.4	3
21	Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. Neuropharmacology, 2020, 168, 107634.	4.1	48
22	Brain insulin action in schizophrenia: Something borrowed and something new. Neuropharmacology, 2020, 163, 107633.	4.1	31
23	Brain insulin action: Implications for the treatment of schizophrenia. Neuropharmacology, 2020, 168, 107655.	4.1	19
24	What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy. Neuropharmacology, 2020, 163, 107591.	4.1	16
25	Further in vivo characterization of [¹¹ C]â€(+)â€PHNO uptake into a retina-like region of interest in humans. Synapse, 2020, 74, e22135.	1.2	1
26	Assessing analytic and intuitive reasoning using the cognitive reflection test in young patients with schizophrenia. Psychiatry Research, 2020, 284, 112683.	3.3	5
27	Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 99, 109839.	4.8	16
28	Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia. Schizophrenia Research, 2020, 223, 279-288.	2.0	5
29	Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. Journal of Psychiatric Research, 2020, 124, 151-158.	3.1	31
30	Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: A Double-Blind Randomized Pilot Study. Biological Psychiatry, 2020, 87, S414.	1.3	0
31	DAS: The Diabetes Awareness and Insight Scale. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 189-194.	3.6	7
32	Improving Insight in Non-Treatment-Resistant Patients With Schizophrenia With Transcranial Direct Current Stimulation. Biological Psychiatry, 2020, 87, S186.	1.3	0
33	Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. European Psychiatry, 2019, 61, 63-71.	0.2	12
34	Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment. Journal of Neuroimaging, 2019, 29, 721-729.	2.0	6
35	S43. Structural Brain Differences Between Cognitively Impaired Patients With and Without Apathy. Biological Psychiatry, 2019, 85, S313.	1.3	0
36	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. Schizophrenia Research, 2019, 208, 420-429.	2.0	32

#	ARTICLE	IF	CITATIONS
37	S167. Increased N-Acetylaspartate and Myo-Inositol Levels in Clozapine-Responders and Clozapine-Resistant Patients With Schizophrenia. <i>Biological Psychiatry</i> , 2019, 85, S361-S362.	1.3	0
38	S185. Treatment Response Trajectories in Treatment-Resistant Schizophrenia: A Chart Review Study. <i>Biological Psychiatry</i> , 2019, 85, S368-S369.	1.3	0
39	The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 207-213.	4.8	5
40	A meta-analysis of transcranial direct current stimulation for schizophrenia: "œs more better?â€. <i>Journal of Psychiatric Research</i> , 2019, 110, 117-126.	3.1	40
41	Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry</i> , 2019, 85, 596-605.	1.3	94
42	Reward motivation in humans and its relationship to dopamine D2/3 receptor availability: A pilot study with dual [11C]-raclopride and [11C]-(+)-PHNO imaging. <i>Journal of Psychopharmacology</i> , 2018, 32, 357-366.	4.0	10
43	OASIS: The Obesity Awareness and Insight Scale. <i>Obesity Medicine</i> , 2018, 9, 38-44.	0.9	9
44	Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. <i>Psychiatry Research - Neuroimaging</i> , 2018, 273, 16-24.	1.8	14
45	Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. <i>European Neuropsychopharmacology</i> , 2018, 28, 285-296.	0.7	6
46	Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis of 1H-MRS studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 340-352.	4.8	49
47	<scp>BASIS</scp>: The blood pressure awareness and insight scale. <i>Journal of Clinical Hypertension</i> , 2018, 20, 748-756.	2.0	9
48	The neural correlates of apathy in schizophrenia: An exploratory investigation. <i>Neuropsychologia</i> , 2018, 118, 34-39.	1.6	9
49	Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 523-530.	2.7	11
50	Trait impulsivity is not related to post-commissural putamen volumes: A replication study in healthy men. <i>PLoS ONE</i> , 2018, 13, e0209584.	2.5	7
51	Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 622.	2.6	115
52	The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. <i>Psychiatry Research</i> , 2018, 268, 114-122.	3.3	62
53	Reprint of OASIS "œ“ Obesity Awareness and Insight Scale. <i>Primary Care Diabetes</i> , 2018, 12, 371-378.	1.8	2
54	F6. Is it Possible to Elicit Progressive Functioning Decline Without Having Beta-Amyloid Pathology? Clinical Trajectories of Mild Cognitive Impairment With Suspected Non-Alzheimer's Pathology. <i>Biological Psychiatry</i> , 2018, 83, S239.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. <i>Experimental Eye Research</i> , 2018, 175, 32-41.	2.6	16
56	Exploring the relationship between social attachment and dopamine D _{2/3} receptor availability in the brains of healthy humans using [¹¹ C]-(+)-PHNO. <i>Social Neuroscience</i> , 2017, 12, 163-173.	1.3	12
57	Impaired illness awareness and leftward visuospatial inattention in schizophrenia are attributable to a common neural deficit – Posterior parietal hemispheric imbalance. <i>Medical Hypotheses</i> , 2017, 100, 19-22.	1.5	1
58	Is antipsychotic sensitivity in Alzheimer’s disease secondary to abnormal blood-brain barrier integrity?. <i>Brain</i> , 2017, 140, 865-867.	7.6	2
59	Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning. <i>Psychoneuroendocrinology</i> , 2017, 81, 80-87.	2.7	10
60	Structural and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Amyloid Pathology: A 2-Year Longitudinal Study. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, S122-S123.	1.2	0
61	Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2017, 43, 764-777.	4.3	159
62	Trait impulsiveness is related to smaller post-commissural putamen volumes in males but not females. <i>European Journal of Neuroscience</i> , 2017, 46, 2253-2264.	2.6	10
63	The relationship between subcortical brain volume and striatal dopamine D _{2/3} receptor availability in healthy humans assessed with [¹¹ C]raclopride and [¹¹ C]-(+)-PHNO. <i>Human Brain Mapping</i> , 2017, 38, 5519-5534.	3.6	12
64	Exploring the Relationship Between Body Mass Index and Positive Symptom Severity in Persons at Clinical High Risk for Psychosis. <i>Journal of Nervous and Mental Disease</i> , 2017, 205, 893-895.	1.0	9
65	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer’s Disease Pathology. <i>Journal of Alzheimer’s Disease</i> , 2017, 58, 747-762.	2.6	9
66	Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1-10.	1.2	18
67	The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer’s Pathology: A Brief Report. <i>Journal of Alzheimer’s Disease</i> , 2017, 60, 341-347.	2.6	4
68	Benzodiazepine Use Reduces Cortical Beta-Amyloid Levels and is Not Associated with Progressive Cognitive Decline in Non-Demented Elderly Adults: A Pilot Study Using F18-Florbetapir Positron Emission Tomography. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, S136-S138.	1.2	1
69	Exploring personality traits related to dopamine D2/3 receptor availability in striatal subregions of humans. <i>European Neuropsychopharmacology</i> , 2016, 26, 644-652.	0.7	23
70	Benzodiazepine Use Attenuates Cortical β^2 -Amyloid and is Not Associated with Progressive Cognitive Decline in Nondemented Elderly Adults: A Pilot Study Using F18-Florbetapir Positron Emission Tomography. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 1028-1039.	1.2	19
71	β^2 -Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 923-939.	1.2	15
72	Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. <i>Psychopharmacology</i> , 2016, 233, 3803-3813.	3.1	11

#	ARTICLE	IF	CITATIONS
73	Estimating the effect of endogenous dopamine on baseline [¹¹ C]-(+)-PHNO binding in the human brain. <i>Synapse</i> , 2016, 70, 453-460.	1.2	12
74	Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 149-159.	2.3	38
75	The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 49-53.	4.8	17
76	Lack of Age-Dependent Decrease in Dopamine D3 Receptor Availability: A [¹¹ C]-(+)-PHNO and [¹¹ C]-Raclopride Positron Emission Tomography Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1812-1818.	4.3	26
77	Lifetime History of Depression Predicts Increased Beta-Amyloid Accumulation in Patients with Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, S147-S150.	1.2	1
78	Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 743-754.	2.6	33
79	Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv014-pyv014.	2.1	59
80	Lifetime History of Depression Predicts Increased Amyloid- β Accumulation in Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 907-919.	2.6	49
81	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. <i>Schizophrenia Research</i> , 2015, 161, 429-433.	2.0	22
82	Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia: A [¹¹ C]-raclopride PET study. <i>Schizophrenia Research</i> , 2015, 164, 263-267.	2.0	17
83	Examining endogenous dopamine in treated schizophrenia using [¹¹ C]-(+)-PHNO positron emission tomography: A pilot study. <i>Clinica Chimica Acta</i> , 2015, 449, 60-62.	1.1	29
84	Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 927.	11.0	77
85	Neuroimaging findings in treatment-resistant schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2015, 164, 164-175.	2.0	75
86	Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. <i>Medical Hypotheses</i> , 2015, 85, 391-396.	1.5	11
87	Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. <i>Schizophrenia Bulletin</i> , 2015, 42, sbv106.	4.3	16
88	Ventral Striatum Binding of a Dopamine D2/3 Receptor Agonist But Not Antagonist Predicts Normal Body Mass Index. <i>Biological Psychiatry</i> , 2015, 77, 196-202.	1.3	53
89	Estimating Endogenous Dopamine Levels at D2 and D3 Receptors in Humans using the Agonist Radiotracer [¹¹ C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2014, 39, 2769-2776.	5.4	31
90	The VAGUS insight into psychosis scale: Self-report and clinician-rated versions. <i>Psychiatry Research</i> , 2014, 220, 1084-1089.	3.3	41

#	ARTICLE	IF	CITATIONS
91	The VAGUS- Self-Report & Clinician-Rated Versions: A Novel Insight into Psychosis Scale for Use Across the Adult Late-Life Span. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, S93-S94.	1.2	0
92	Glutamate-mediated excitotoxicity in schizophrenia: A review. <i>European Neuropsychopharmacology</i> , 2014, 24, 1591-1605.	0.7	115
93	Occupancy of Dopamine D3 Receptors by Aripiprazole in Treatment Resistant Late-Life Depressed Patients Depends on Length of Treatment as Evidenced by in vivo Imaging with [11C]-(+)-PHNO. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, S83-S84.	1.2	4
94	Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. <i>Psychopharmacology</i> , 2013, 228, 43-51.	3.1	15
95	The potential role of dopamine D3 receptor neurotransmission in cognition. <i>European Neuropsychopharmacology</i> , 2013, 23, 799-813.	0.7	153